In Partnership with Medscape

The Next Level of Clarity:

Why CAD Risk Needs More Than Surrogate Markers

Watch Webinar On Demand

Watch Webinar Now

Please fill out the form to view the webinar and download the presentation slide decks.

Join renowned preventive cardiologists Joel Kahn, MD, FACC, and Arthur Agatston, MD, FACC, moderated by Jim Min, MD, CEO of Cleerly, for an in-depth discussion on the future of coronary artery disease (CAD) diagnosis and treatment. This session will explore how AI-enabled analysis of coronary CT angiography (CTA) is redefining CAD risk assessment and empowering clinicians to move beyond traditional surrogate markers. Through real-world case studies, Drs Kahn and Agatston will share how they integrate Cleerly’s technology into their practices to personalize care and help prevent future cardiac events.

Request Your Cleerly Demo

Contact us for a one-on-one software demonstration with a Cleerly expert to see how bringing Cleerly’s AI‑driven CCTA analysis to your organization can empower you to provide personalized treatment decisions for your patients.

Request a Demo